Immunotherapy has become a major treatment for advanced renal cell carcinoma and is also used after surgery in selected patients at higher risk of recurrence. These medicines stimulate or release brakes on the immune system so it can attack cancer cells. Common kidney-cancer regimens use immune checkpoint inhibitors, sometimes in combination with another immunotherapy drug or a targeted therapy. Immunotherapy is not needed for every kidney cancer, and it is not the same as chemotherapy. The choice depends on stage, histology, recurrence risk, previous treatment, other illnesses and the expected balance of benefit and immune-related side effects.

Where is immunotherapy used in kidney cancer?

• First-line treatment of many metastatic clear-cell renal cell cancers
• In combinations such as immunotherapy plus a VEGF-targeted tyrosine kinase inhibitor
• Dual immune checkpoint blockade in selected metastatic patients
• Adjuvant pembrolizumab after surgery in selected high-risk clear-cell RCC after discussion of benefits and risks

How checkpoint inhibitors work

Cancer cells can exploit immune “checkpoints” that normally prevent excessive immune activity. Drugs targeting PD-1, PD-L1 or CTLA-4 can restore immune recognition. Because the immune system becomes more active, side effects may involve almost any organ.

Immune-related side effects

• Skin rash or itching
• Diarrhoea/colitis
• Liver inflammation
• Thyroid or other hormone-gland inflammation
• Lung inflammation causing cough or breathlessness
• Kidney inflammation
• Rare neurological, cardiac or other severe immune reactions

Why early reporting matters

Immune side effects can begin during treatment or occasionally after it has stopped. Many are manageable when recognised early, but serious toxicity can worsen quickly. Report new diarrhoea, breathlessness, severe fatigue, jaundice, persistent headache, weakness or marked changes in urine rather than waiting for the next scheduled visit.

How response is monitored

Clinical symptoms, blood tests and periodic CT imaging are used. Some patients have durable responses, while others do not respond. Treatment may be paused or stopped for toxicity, progression or after a planned duration depending on the regimen.

Immune side effects are different from chemotherapy side effects

Checkpoint inhibitors can activate the immune system against normal organs as well as cancer. Thyroid inflammation, hepatitis, colitis, pneumonitis, adrenal or pituitary problems and nephritis can occur even after earlier cycles were uneventful. New persistent diarrhoea, breathlessness, jaundice, severe fatigue or unusual headache should therefore be reported early rather than treated only symptomatically at home.

Why combinations are common in metastatic RCC

Modern first-line treatment for clear-cell metastatic RCC commonly combines immunotherapy with another immunotherapy or a VEGF-targeted drug. The choice is influenced by IMDC risk, comorbidity, autoimmune history, blood pressure, liver function, disease tempo and the need for a rapid response. “Immunotherapy” is therefore not one drug or one standard regimen.

Adjuvant immunotherapy is a different decision

Selected patients with resected high-risk clear-cell RCC may be offered adjuvant pembrolizumab after surgery. That discussion is about lowering recurrence risk in a patient who may already be cured by surgery, so potential benefit must be weighed against immune toxicity and overtreatment. It is different from treating visible metastatic disease.

Immune toxicity can appear outside the organ you expect

Checkpoint inhibitors can inflame almost any organ, so side effects do not always look like “chemotherapy toxicity.” New diarrhoea, cough, breathlessness, jaundice, severe fatigue, headache, visual change or unusual weakness deserves early discussion because immune-related inflammation may need blood tests, imaging, hormone testing or corticosteroid treatment. Do not self-treat persistent symptoms for days simply because the previous cycles were well tolerated.

When to seek earlier medical review

During immunotherapy, report persistent diarrhoea, new cough/breathlessness, jaundice, severe fatigue, unusual headache, visual symptoms, marked weakness or reduced urine output promptly. Immune toxicity can worsen quickly and may require treatment even when the cancer therapy itself is working.

What to bring to your consultation

• Pathology and staging scans
• Current treatment protocol/cycle dates
• Recent blood tests and thyroid/liver/kidney results
• Complete medicine/supplement list

Questions to ask your doctor

• Which immune regimen are you recommending and why?
• Which immune-related symptoms should trigger a same-day call?
• Am I discussing treatment of metastatic disease or adjuvant treatment after surgery?

FAQs

Related reading

• Kidney Cancer: Symptoms and Treatment
• CT Scan for Kidney Cancer
• Partial Nephrectomy Explained
• Radical Nephrectomy Explained
• Kidney Cancer Follow-Up
• Chemotherapy and Immunotherapy for Advanced Bladder Cancer
• Urologist in Latur

References

• European Association of Urology (EAU). Renal Cell Carcinoma Guidelines, 2026. Diagnostic Evaluation https://uroweb.org/guidelines/renal-cell-carcinoma/chapter/diagnostic-evaluation
• European Association of Urology (EAU). Renal Cell Carcinoma Guidelines, 2026. Disease Management https://uroweb.org/guidelines/renal-cell-carcinoma/chapter/disease-management
• European Association of Urology (EAU). Renal Cell Carcinoma Guidelines, 2026. Follow-up in RCC https://uroweb.org/guidelines/renal-cell-carcinoma/chapter/followup-in-rcc
• National Cancer Institute. Renal Cell Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq